2L treatment choices and response rate in MER and LEO cohorts
2L therapy . | MER (N = 949) . | LEO (N = 2755) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PPD (n = 40) . | EOT PR (n = 40) . | Early relapse (n = 52) . | Total (n = 132) . | P . | PPD (n = 145) . | EOT PR (n = 66) . | Early relapse (n = 97) . | Total (n = 308) . | P . | |
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | |||
| Platinum-based chemotherapy | 33 (82.5) | 29 (76.3) | 27 (52.9) | 89 (69.0) | .002 | 91 (64.5) | 34 (59.6) | 41 (45.6) | 166 (57.6) | .011 |
| Other systemic chemotherapy | 4 (10.0) | 2 (5.3) | 11 (21.6) | 17 (13.2) | 6 (4.2) | 4 (7.0) | 11 (12.2) | 21 (7.3) | ||
| Primarily CNS directed | 3 (7.5) | 1 (2.6) | 11 (21.6) | 15 (11.6) | 7 (4.9) | 9 (15.8) | 17 (18.9) | 33 (11.5) | ||
| Radiation/resection | 0 (0) | 6 (15.8) | 2 (3.9) | 8 (6.2) | 12 (8.5) | 3 (5.3) | 7 (7.8) | 22 (7.7) | ||
| Targeted therapies | N/A | 11 (7.8) | 3 (5.3) | 11 (12.2) | 25 (8.7) | |||||
| CAR-T (no bridging) | N/A | 10 (7.0) | 4 (7.0) | 2 (2.2) | 16 (5.6) | |||||
| No treatment | N/A | 4 (2.8) | 0 (0) | 1 (1.1) | 5 (1.7) | |||||
| Missing/unknown | 0 | 2 | 1 | 3 | 4 | 9 | 7 | 20 | ||
2L therapy . | MER (N = 949) . | LEO (N = 2755) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PPD (n = 40) . | EOT PR (n = 40) . | Early relapse (n = 52) . | Total (n = 132) . | P . | PPD (n = 145) . | EOT PR (n = 66) . | Early relapse (n = 97) . | Total (n = 308) . | P . | |
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | |||
| Platinum-based chemotherapy | 33 (82.5) | 29 (76.3) | 27 (52.9) | 89 (69.0) | .002 | 91 (64.5) | 34 (59.6) | 41 (45.6) | 166 (57.6) | .011 |
| Other systemic chemotherapy | 4 (10.0) | 2 (5.3) | 11 (21.6) | 17 (13.2) | 6 (4.2) | 4 (7.0) | 11 (12.2) | 21 (7.3) | ||
| Primarily CNS directed | 3 (7.5) | 1 (2.6) | 11 (21.6) | 15 (11.6) | 7 (4.9) | 9 (15.8) | 17 (18.9) | 33 (11.5) | ||
| Radiation/resection | 0 (0) | 6 (15.8) | 2 (3.9) | 8 (6.2) | 12 (8.5) | 3 (5.3) | 7 (7.8) | 22 (7.7) | ||
| Targeted therapies | N/A | 11 (7.8) | 3 (5.3) | 11 (12.2) | 25 (8.7) | |||||
| CAR-T (no bridging) | N/A | 10 (7.0) | 4 (7.0) | 2 (2.2) | 16 (5.6) | |||||
| No treatment | N/A | 4 (2.8) | 0 (0) | 1 (1.1) | 5 (1.7) | |||||
| Missing/unknown | 0 | 2 | 1 | 3 | 4 | 9 | 7 | 20 | ||
| Response rate to 2L therapy∗ . | n (%) . | n (%) . | n (%) . | n (%) . | P . | n (%) . | n (%) . | n (%) . | n (%) . | P . |
|---|---|---|---|---|---|---|---|---|---|---|
| CR | 3 (7.9) | 3 (10.3) | 16 (35.6) | 21 (20.0) | .009 | 25 (20.8) | 16 (32.7) | 40 (52.6) | 81 (33.1) | <.001 |
| PR | 12 (31.6) | 15 (51.7) | 15 (33.3) | 42 (40.0) | 27 (22.5) | 16 (32.7) | 15 (19.7) | 58 (23.7) | ||
| Stable disease | 2 (5.3) | 3 (10.3) | 3 (6.7) | 8 (7.6) | 9 (7.5) | 4 (8.2) | 4 (5.3) | 17 (6.9) | ||
| PD | 21 (55.3) | 8 (27.5) | 11 (24.4) | 34 (32.4) | 59 (49.2) | 13 (26.4) | 17 (22.4) | 89 (36.3) | ||
| Not applicable/missing† | 2 | 11 | 7 | 27 | 25 | 17 | 21 | 63 |
| Response rate to 2L therapy∗ . | n (%) . | n (%) . | n (%) . | n (%) . | P . | n (%) . | n (%) . | n (%) . | n (%) . | P . |
|---|---|---|---|---|---|---|---|---|---|---|
| CR | 3 (7.9) | 3 (10.3) | 16 (35.6) | 21 (20.0) | .009 | 25 (20.8) | 16 (32.7) | 40 (52.6) | 81 (33.1) | <.001 |
| PR | 12 (31.6) | 15 (51.7) | 15 (33.3) | 42 (40.0) | 27 (22.5) | 16 (32.7) | 15 (19.7) | 58 (23.7) | ||
| Stable disease | 2 (5.3) | 3 (10.3) | 3 (6.7) | 8 (7.6) | 9 (7.5) | 4 (8.2) | 4 (5.3) | 17 (6.9) | ||
| PD | 21 (55.3) | 8 (27.5) | 11 (24.4) | 34 (32.4) | 59 (49.2) | 13 (26.4) | 17 (22.4) | 89 (36.3) | ||
| Not applicable/missing† | 2 | 11 | 7 | 27 | 25 | 17 | 21 | 63 |
Early relapse defined as patients relapsing within 12 months after EOT.
N/A, not applicable; ESHAP-R, Rituximab, etoposide, cisplatin, cytarabine and prednisone; CEPP- cyclophosphamide, etoposide, procarbazine and prednisone; axi-cel, axicabtagene ciloleucel; tisa-cel, tisagenlecleucel.
Treatment groups/Abbreviations: Platinum-based chemotherapy: R-ICE (n = 172), R-DHAP (n = 46), R- guanosine diphosphate (n = 17), R-DHAX (n = 9), HyperCVAD (n = 3), DA-EPOCH-(R)(n = 4), ESHAP-(R) (n = 4); other systemic chemotherapy: CEPP (n = 2), ROAD (n = 5), R-GemOx (n = 16), R-cyclophosphamide(n = 1), R-Bendamustine(n = 1); primarily CNS-directed: single-agent high-dose methotrexate (HD MTX; n = 16), HDMTX, rituximab and temozolomide (MRT; n = 21), cytarabine/HD MTX (n = 7); MATRIX (n = 3), ibrutinib + intrathecal MTX (n = 1). Targeted therapies: ibrutinib (n = 2); polatuzumab vedotin, rituximab with and without bendamustin (n = 2); rituximab-lenalidomide (n = 10); rituximab-lenalidomide-ibrutinib (n = 2); venetoclax (n = 2); loncastuximab tesirine (n = 1); selinexor (n = 1); pembrolizumab (n = 2); and single-agent rituximab with and without prednisone (n = 3). CAR-T: cellular therapy with axi-cel, tisa-cel directly without bridging therapy (n = 15), and mosunetuzumab (n = 1).
Response rate determined by 2014 Lugano response criteria.21
Includes patients who received radiation/resection or no treatment as 2L therapy; in the LEO cohort, also includes patients with no imaging assessment (n = 9).